A client with chronic kidney disease has received epoetin alfa for 4 weeks. Which finding best supports that the therapy is effective?

Epoetin alfa stimulates red blood cell production to reduce anemia and transfusion needs. A gradual hemoglobin rise with improved fatigue supports effectiveness, while hypertension or an excessive hemoglobin target increases harm.

Quick answer
A gradual hemoglobin increase with less fatigue indicates the intended epoetin alfa response.

Why this is correct
Chronic kidney disease can reduce endogenous erythropoietin and red-cell production. Epoetin alfa should produce a monitored rise in hemoglobin and improve anemia-related symptoms while the dose is adjusted to avoid rapid or excessive elevation.

Easy analogy or mental picture
Epoetin is like increasing a factory's red-cell production at a controlled rate. The analogy explains the gradual response but does not set a universal hemoglobin target or replace dose-specific monitoring.

Memory hook
Epoetin success is gradual hemoglobin recovery with fewer anemia symptoms.

NCLEX decision rule
Judge an erythropoiesis-stimulating agent by controlled hematologic improvement, not by unrelated electrolyte change. Treat hypertension or an excessive hemoglobin rise as a safety concern requiring reassessment.

Why the other choices are wrong
Marked hypertension is an adverse effect. A high hemoglobin without dose review increases cardiovascular risk, and epoetin is not intended to lower potassium.